<SEC-DOCUMENT>0000950170-25-003781.txt : 20250110
<SEC-HEADER>0000950170-25-003781.hdr.sgml : 20250110
<ACCEPTANCE-DATETIME>20250110070818
ACCESSION NUMBER:		0000950170-25-003781
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		13
CONFORMED PERIOD OF REPORT:	20250110
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250110
DATE AS OF CHANGE:		20250110

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Invivyd, Inc.
		CENTRAL INDEX KEY:			0001832038
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				851403134
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40703
		FILM NUMBER:		25520370

	BUSINESS ADDRESS:	
		STREET 1:		1601 TRAPELO ROAD
		STREET 2:		SUITE 178
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02451
		BUSINESS PHONE:		(781) 819-0080

	MAIL ADDRESS:	
		STREET 1:		1601 TRAPELO ROAD
		STREET 2:		SUITE 178
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02451

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Adagio Therapeutics, Inc.
		DATE OF NAME CHANGE:	20201112
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ivvd-20250110.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2025-01-09T23:03:35.4108+00:00 -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ivvd="http://invivyd.com/20250110" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:utr="http://www.xbrl.org/2009/utr">
 <head>
  <title>8-K</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="margin: auto!important;padding: 8px;line-height: 1;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_9c8ac2df-68b9-403d-b9cf-c50b29b4e6fd" name="dei:EntityCentralIndexKey" contextRef="C_c09dbd9c-d13c-4ed8-a2ee-bedecadfa843">0001832038</ix:nonNumeric><ix:nonNumeric id="F_2c65da4c-95a8-4673-bf11-2cdbd89cfd3e" name="dei:AmendmentFlag" contextRef="C_c09dbd9c-d13c-4ed8-a2ee-bedecadfa843" format="ixt:fixed-false">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="ivvd-20250110.xsd"/></ix:references><ix:resources><xbrli:context id="C_c09dbd9c-d13c-4ed8-a2ee-bedecadfa843"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832038</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-10</xbrli:startDate><xbrli:endDate>2025-01-10</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">UNITED STATES</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">WASHINGTON, D.C. 20549</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;border-bottom:1pt solid #000000;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">FORM </span><span style="font-size:18pt;font-family:Times New Roman;"><ix:nonNumeric id="F_410338d0-029b-4240-ba54-2c53e0e85591" contextRef="C_c09dbd9c-d13c-4ed8-a2ee-bedecadfa843" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">8-K</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;border-bottom:1pt solid #000000;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">CURRENT REPORT</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to Section 13 or 15(d)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">of the Securities Exchange Act of 1934</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Date of report (Date of earliest event reported): </span><span style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_17a0ead3-e143-4628-b8a8-a8951a0826d1" contextRef="C_c09dbd9c-d13c-4ed8-a2ee-bedecadfa843" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">January 10, 2025</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;border-bottom:1pt solid #000000;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:24pt;font-family:Times New Roman;"><ix:nonNumeric id="F_052c7da8-a25d-4113-9a8b-4e7e97b7799f" contextRef="C_c09dbd9c-d13c-4ed8-a2ee-bedecadfa843" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:24pt;font-family:Times New Roman;min-width:fit-content;">Invivyd, Inc.</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(Exact Name of Registrant as Specified in its Charter)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;border-bottom:1pt solid #000000;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:34.58%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:30.78%;box-sizing:content-box;"/>
    <td style="width:3.8%;box-sizing:content-box;"/>
    <td style="width:29.84%;box-sizing:content-box;"/>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_64ef4eb7-76ea-4729-9de9-7cfb5dea47d9" contextRef="C_c09dbd9c-d13c-4ed8-a2ee-bedecadfa843" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_0b31e729-c4dd-4d24-83ca-b45d888a2d2e" contextRef="C_c09dbd9c-d13c-4ed8-a2ee-bedecadfa843" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">001-40703</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_3500c13c-406f-4c12-bd8c-9df4d2c234df" contextRef="C_c09dbd9c-d13c-4ed8-a2ee-bedecadfa843" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">85-1403134</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(State or Other Jurisdiction</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">of Incorporation)</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Commission</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">File Number)</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(IRS Employer</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Identification No.)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:49.04%;box-sizing:content-box;"/>
    <td style="width:9.62%;box-sizing:content-box;"/>
    <td style="width:41.34%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_b21ff062-24a2-4d3e-811e-0d3a7d54e98a" contextRef="C_c09dbd9c-d13c-4ed8-a2ee-bedecadfa843" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">1601 Trapelo Road</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">, </span><span><ix:nonNumeric id="F_208effd1-72b0-4405-aa9b-bb5ba3eb6f24" contextRef="C_c09dbd9c-d13c-4ed8-a2ee-bedecadfa843" name="dei:EntityAddressAddressLine2"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Suite 178</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span><ix:nonNumeric id="F_73d56382-0a18-41c4-9817-e467731b3c6b" contextRef="C_c09dbd9c-d13c-4ed8-a2ee-bedecadfa843" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Waltham</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">, </span><span><ix:nonNumeric id="F_541360b5-fca8-42ed-8400-574aa2dda016" contextRef="C_c09dbd9c-d13c-4ed8-a2ee-bedecadfa843" name="dei:EntityAddressStateOrProvince"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">MA</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_2895713c-b89f-4df6-8d2f-473908061e81" contextRef="C_c09dbd9c-d13c-4ed8-a2ee-bedecadfa843" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">02451</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Address of Principal Executive Offices)</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Zip Code)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Registrant&#8217;s telephone number, including area code: (</span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_067a2c4e-923c-4903-a883-a8081a4ceece" contextRef="C_c09dbd9c-d13c-4ed8-a2ee-bedecadfa843" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">781</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">) </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9b5d0bc5-ec1c-4eb0-930d-b8febe54c53e" contextRef="C_c09dbd9c-d13c-4ed8-a2ee-bedecadfa843" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">819-0080</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Not applicable</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(Former Name or Former Address, if Changed Since Last Report)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;border-bottom:1pt solid #000000;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:2.36%;box-sizing:content-box;"/>
    <td style="width:97.64%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_18657e40-9dbe-4b63-83fc-4c731b9f0d9a" contextRef="C_c09dbd9c-d13c-4ed8-a2ee-bedecadfa843" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:2.34%;box-sizing:content-box;"/>
    <td style="width:97.66%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_2db754d5-2701-4ca9-8316-a1fdf6ccca8e" contextRef="C_c09dbd9c-d13c-4ed8-a2ee-bedecadfa843" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:1.88%;box-sizing:content-box;"/>
    <td style="width:98.12%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_778a6a69-402e-4c43-b35a-6782ac322659" contextRef="C_c09dbd9c-d13c-4ed8-a2ee-bedecadfa843" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:1.9%;box-sizing:content-box;"/>
    <td style="width:98.1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_0d75b068-9618-4645-baf9-1ad831567eb3" contextRef="C_c09dbd9c-d13c-4ed8-a2ee-bedecadfa843" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:51.41%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:9.142%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:37.447%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:1pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Title of each class</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:1pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:1pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Trading</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Symbol(s)</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:1pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:1pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Name of each exchange</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">on which registered</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_99e3ab40-2c34-412b-8999-0105ae535aec" contextRef="C_c09dbd9c-d13c-4ed8-a2ee-bedecadfa843" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Common stock, par value $0.0001 per share</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_36e35d58-3906-44be-bee8-6287ce688798" contextRef="C_c09dbd9c-d13c-4ed8-a2ee-bedecadfa843" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">IVVD</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_e59924ca-8edd-40ac-a577-12fd3c36023b" contextRef="C_c09dbd9c-d13c-4ed8-a2ee-bedecadfa843" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">The Nasdaq Stock Market LLC</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Emerging growth company </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ce489f2b-3aff-42c4-a17f-c4de5d1315c0" contextRef="C_c09dbd9c-d13c-4ed8-a2ee-bedecadfa843" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_53d2befa-964f-44ac-9ec8-c1bf7fc89e91" contextRef="C_c09dbd9c-d13c-4ed8-a2ee-bedecadfa843" name="dei:EntityExTransitionPeriod" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:10.58%;box-sizing:content-box;"/>
    <td style="width:89.42%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Item 8.01.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Other Events.</span></p></td>
   </tr>
  </table>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On January 10, 2025, Invivyd, Inc. issued a press release entitled &#8220;Invivyd Announces Continued Neutralizing Activity of PEMGARDA&#153; (pemivibart) against dominant SARS-CoV-2 Variant XEC.&#8221; A copy of the press release is filed herewith as Exhibit 99.1 and is incorporated by reference in this Item 8.01.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:10.58%;box-sizing:content-box;"/>
    <td style="width:89.42%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Item 9.01.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Financial Statements and Exhibits.</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(d) Exhibits</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:5.88%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:93.12%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid #000000;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Exhibit<br/>No.</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid #000000;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Description</span></p></td>
   </tr>
   <tr style="height:14.4pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">99.1</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="ivvd-ex99_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Press Release, dated January 10, 2025</span></a></p></td>
   </tr>
   <tr style="height:14.4pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">104</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SIGNATURES</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> 	</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">					</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.496%;box-sizing:content-box;"/>
    <td style="width:4.003%;box-sizing:content-box;"/>
    <td style="width:4.003%;box-sizing:content-box;"/>
    <td style="width:46.497%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">INVIVYD, INC.</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date: January 10, 2025</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.25pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Jill Andersen</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Jill Andersen</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Chief Legal Officer and Corporate Secretary</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ivvd-ex99_1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html>
 <head>
  <title>EX-99.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;line-height: 1;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Exhibit 99.1</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img59752938_0.jpg" alt="img59752938_0.jpg" style="width:240px;height:36px;"></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Aptos',sans-serif;min-width:fit-content;">invivyd Announces Continued Neutralizing Activity of PEMGARDA&#153; (pemivibart) Against Dominant SARS-CoV-2 Variant XEC</font><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Aptos',sans-serif;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-style:italic;min-width:fit-content;">New in vitro neutralization data show continued, consistent neutralizing activity of PEMGARDA&#153; (pemivibart) against XEC </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-style:italic;min-width:fit-content;">Centers for Disease Control reports XEC and KP.3.1.1 (previously disclosed as susceptible to PEMGARDA) together constitute the majority of national SARS-CoV-2 variants</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-style:italic;min-width:fit-content;">XEC data underscore continued pemivibart activity in the face of virus evolution including recently emerging types of structural changes to spike N-terminal domain</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-style:italic;min-width:fit-content;">Data submitted to FDA, with timely update to PEMGARDA&#153; Fact Sheet for Healthcare Providers anticipated</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;font-style:italic;min-width:fit-content;">Continued consistent activity for almost three years, with no meaningful change to pemivibart neutralization activity anticipated for the foreseeable future if the epitope pemivibart targets remains structurally intact, as it has since Omicron BA.1</font></div></div>
  <p style="font-size:10pt;margin-top:18.75pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;min-width:fit-content;">WALTHAM, Mass., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced that new in vitro neutralization data show continued neutralizing activity of PEMGARDA</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:8.040000000000001pt;font-family:'Aptos',sans-serif;min-width:fit-content;">TM</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;min-width:fit-content;"> (pemivibart) and pipeline candidate VYD2311 against dominant SARS-CoV-2 variant XEC. As anticipated based on the structural biology of pemivibart and VYD2311, the data are largely consistent with those previously reported for KP.3.1.1. The Centers for Disease Control (CDC) estimates that XEC and KP.3.1.1 accounted for an aggregate 69% of U.S. circulating variants of SARS-CoV-2 for the two weeks ended December 21, 2024. Invivyd generated these new data as part of its ongoing industrial virology effort, which leverages a consistent, high-quality, independent, third-party pseudoviral system that routinely tests authentic Invivyd-produced pemivibart and is supported by extensive structure-based and proprietary analytics.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:18.75pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;min-width:fit-content;">Invivyd has demonstrated positive PEMGARDA neutralization activity against over 75% of currently circulating U.S. variants, and all prior variants, tested to date. Further, the company estimates that every clinical variant reported in the CDC COVID Tracker since the Omicron BA.1 lineage has been susceptible to pemivibart even if untested due to the consistent structural integrity of the pemivibart epitope. Therefore, Invivyd does not anticipate any meaningful change to pemivibart neutralization activity, aside from expected normal quantitative variation in assay output, for the foreseeable future if the epitope pemivibart targets remains structurally intact, as it has since Omicron BA.1.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;min-width:fit-content;">  </font></p>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;min-width:fit-content;">&#x201c;We designed pemivibart and our pipeline molecules to resist the effects of evolution,&#x201d; said Robert Allen, Ph.D., Chief Scientific Officer. &#x201c;Pemivibart has now demonstrated antiviral activity in neutralization assays representing thirty-nine distinct SARS-CoV-2 variants across almost three years of rapid virus evolution.  The ongoing pemivibart activity, with minimal quantitative change in neutralization activity, especially as compared to predecessor medicines such as Evusheld&#153; (tixagavimab/cilgavimab), is incredibly reassuring and validating of our fundamental R&amp;D engine and potentiates our ability to successfully drug this target for long periods of time despite evolutionary pressure.&#x201d;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;min-width:fit-content;">&#x201c;Invivyd has worked to construct what we believe is the world&#x2019;s most advanced and capable antibody discovery and virology platform designed to provide best-in-class molecules and virologic assessment,&#x201d; noted Marc Elia, Chairman of Invivyd Board of Directors. &#x201c;Therefore, we are pleased but not surprised by today&#x2019;s robust data that confirm ongoing PEMGARDA&#153; (pemivibart) neutralizing activity against key current circulating viral lineages.&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;min-width:fit-content;">&#x201c;Amidst the continual mutations that characterize SARS-CoV-2, proactively monitoring viral evolution as Invivyd is doing is a necessity in order to continuously test PEMGARDA against emerging variants of SARS-CoV- 2,&#x201d; noted Amesh Adalja, MD, FIDSA, FACP, FACEP, Senior Scholar, Johns Hopkins Center for Health Security. &#x201c;It is reassuring that PEMGARDA continues to show neutralizing activity against XEC, the current dominant circulating variant in the U.S. As we see COVID-19 numbers continue to rise through the respiratory season, PEMGARDA offers a valuable tool for certain moderately to severely immunocompromised patients who need options.&#x201d;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;min-width:fit-content;">Data showing continued in vitro neutralizing activity of PEMGARDA&#153; (pemivibart) against XEC have been submitted to the U.S. Food and Drug Administration (FDA), with a timely update to the PEMGARDA Fact Sheet for Healthcare Providers anticipated.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Aptos',sans-serif;min-width:fit-content;">About PEMGARDA</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"><br></font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;min-width:fit-content;">PEMGARDA&#153; (pemivibart) is a half-life extended investigational monoclonal antibody (mAb). PEMGARDA was engineered from adintrevimab, Invivyd&#x2019;s investigational mAb that has a robust safety data package and provided evidence of clinical efficacy in a global Phase 2/3 clinical trial for the prevention and treatment of COVID-19. PEMGARDA has demonstrated in vitro neutralizing activity against major SARS-CoV-2 variants, including JN.1, KP.3.1.1 and XEC. PEMGARDA targets the SARS-CoV-2 spike protein receptor binding domain (RBD), thereby inhibiting virus attachment to the human ACE2 receptor on host cells.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;min-width:fit-content;">PEMGARDA (pemivibart) injection (4500 mg), for intravenous use is an investigational mAb that has not been approved, but has been authorized for emergency use by the U.S. FDA under an EUA for the pre-exposure prophylaxis (prevention) of COVID-19 in adults and adolescents (12 years of age and older weighing at least 40 kg) who have</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;min-width:fit-content;"> </font></p>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;min-width:fit-content;">moderate-to-severe immune compromise due to certain medical conditions or receipt of certain immunosuppressive medications or treatments and are unlikely to mount an adequate immune response to COVID-19 vaccination. Recipients should not be currently infected with or have had a known recent exposure to an individual infected with SARS-CoV-2.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;min-width:fit-content;">PEMGARDA is not authorized for use for treatment of COVID-19 or post-exposure prophylaxis of COVID-19. Pre-exposure prophylaxis with PEMGARDA is not a substitute for vaccination in individuals for whom COVID-19 vaccination is recommended. Individuals for whom COVID-19 vaccination is recommended, including individuals with moderate-to-severe immune compromise who may derive benefit from COVID-19 vaccinations, should receive COVID-19 vaccination. In individuals who have recently received a COVID-19 vaccine, PEMGARDA should be administered at least 2 weeks after vaccination.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;min-width:fit-content;">Anaphylaxis has been observed with PEMGARDA and the PEMGARDA Fact Sheet for Healthcare Providers includes a boxed warning for anaphylaxis. The most common adverse events (all grades, incidence &#x2265;2%) observed in participants who have moderate-to-severe immune compromise treated with PEMGARDA included systemic and local infusion-related or hypersensitivity reactions, upper respiratory tract infection, viral infection, influenza-like illness, fatigue, headache, and nausea. For additional information, please see the PEMGARDA full product Fact Sheet for Healthcare Providers, including important safety information and boxed warning.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;min-width:fit-content;">To support the EUA for PEMGARDA, an immunobridging approach was used to determine if PEMGARDA may be effective for pre-exposure prophylaxis of COVID-19. Immunobridging is based on the serum virus neutralizing titer-efficacy relationships identified with other neutralizing human mAbs against SARS-CoV-2. This includes adintrevimab, the parent mAb of pemivibart, and other mAbs that were previously authorized for EUA. There are limitations of the data supporting the benefits of PEMGARDA. Evidence of clinical efficacy for other neutralizing human mAbs against SARS-CoV-2 was based on different populations and SARS-CoV-2 variants that are no longer circulating. Further, the variability associated with cell-based EC50 value determinations, along with limitations related to pharmacokinetic data and efficacy estimates for the mAbs in prior clinical trials, impact the ability to precisely estimate protective titer ranges. Additionally, certain SARS-CoV-2 viral variants may emerge that have substantially reduced susceptibility to PEMGARDA, and PEMGARDA may not be effective at preventing COVID-19 caused by these SARS-CoV-2 viral variants.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;min-width:fit-content;">The emergency use of PEMGARDA is only authorized for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of drugs and biological products during the COVID-19 pandemic under Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. &#167; 360bbb-3(b)(1), unless the declaration is terminated or authorization revoked sooner.  PEMGARDA is authorized for use only when the combined national frequency of variants with substantially reduced susceptibility to PEMGARDA is less than or equal to 90%, based on available information including variant susceptibility to PEMGARDA and national variant frequencies.</font></p>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Aptos',sans-serif;min-width:fit-content;">About VYD2311</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Aptos',sans-serif;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;min-width:fit-content;">VYD2311 is a novel monoclonal antibody (mAb) candidate being developed for COVID-19 to continue to address the urgent need for new therapeutic options for vulnerable populations, including immunocompromised people.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;min-width:fit-content;">VYD2311 was engineered from adintrevimab, Invivyd&#x2019;s investigational mAb that has a robust safety data package and demonstrated clinically meaningful results in global Phase 3 clinical trials for both the prevention and treatment of COVID-19. The pharmacokinetic profile of VYD2311 may offer the ability to deliver clinically meaningful titer levels through more patient-friendly means such as an intramuscular route of administration.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Aptos',sans-serif;min-width:fit-content;">About Invivyd</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"><br></font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;min-width:fit-content;">Invivyd, Inc. (Nasdaq: IVVD) is a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, beginning with SARS-CoV-2. The company&#x2019;s proprietary INVYMAB&#153; platform approach combines state-of-the-art viral surveillance and predictive modeling with advanced antibody engineering. INVYMAB is designed to facilitate the rapid, serial generation of new monoclonal antibodies (mAbs) to address evolving viral threats. In March 2024, Invivyd received emergency use authorization (EUA) from the U.S. FDA for its first mAb in a planned series of innovative antibody candidates. Visit https://invivyd.com/ to learn more.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;min-width:fit-content;">Trademarks are the property of their respective owners.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Aptos',sans-serif;min-width:fit-content;">Cautionary Note Regarding Forward Looking Statements</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Aptos',sans-serif;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;min-width:fit-content;">This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as &#x201c;anticipates,&#x201d; &#x201c;believes,&#x201d; &#x201c;could,&#x201d; &#x201c;expects,&#x201d; &#x201c;estimates,&#x201d; &#x201c;intends,&#x201d; &#x201c;potential,&#x201d; &#x201c;projects,&#x201d; and &#x201c;future&#x201d; or similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements include statements concerning, among other things, the company&#x2019;s ongoing research and development activities, as well as future potential research and development efforts; the company&#x2019;s ongoing industrial virology effort, which leverages a consistent, high-quality, independent, third-party pseudoviral system that routinely tests authentic Invivyd-produced pemivibart and is supported by extensive structure-based analytics and proprietary analytics; the ongoing in vitro neutralizing activity of PEMGARDA against major SARS-CoV-2 variants; anticipated timely updates to the PEMGARDA Fact Sheet for Healthcare Providers; the company&#x2019;s expectations regarding the neutralization activity of pemivibart for the foreseeable future; the design of pemivibart and the company&#x2019;s pipeline molecules to resist the effects of evolution; the company&#x2019;s beliefs regarding the potential of its fundamental R&amp;D engine and ability to successfully drug its target for long periods of time despite evolutionary pressure; the company&#x2019;s beliefs regarding its antibody discovery and virology platform and its potential to provide best-in-class molecules and virologic</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;min-width:fit-content;"> </font></p>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;min-width:fit-content;">assessment; the potential of PEMGARDA as a mAb for pre-exposure prophylaxis (prevention) of COVID-19 in certain adults and adolescents who have moderate-to-severe immune compromise; the potential ability of VYD2311 to deliver clinically meaningful titer levels through more patient-friendly means such as an intramuscular route of administration; the company&#x2019;s devotion to delivering protection from serious viral infectious diseases, beginning with SARS-CoV-2; the design of the company&#x2019;s INVYMAB platform approach to facilitate the rapid, serial generation of new mAbs to address evolving viral threats; and other statements that are not historical fact. The company may not actually achieve the plans, intentions or expectations disclosed in the company&#x2019;s forward-looking statements and you should not place undue reliance on the company&#x2019;s forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause the company&#x2019;s actual results to differ materially from the results described in or implied by the forward-looking statements, including, without limitation: the timing and progress of the company&#x2019;s discovery, preclinical and clinical development activities; the risk that results of nonclinical studies or clinical trials may not be predictive of future results, and interim data are subject to further analysis; unexpected safety or efficacy data observed during preclinical studies or clinical trials; the predictability of clinical success of the company&#x2019;s product candidates based on neutralizing activity in nonclinical studies; potential variability in neutralizing activity of product candidates tested in different assays, such as pseudovirus assays and authentic assays; the company&#x2019;s reliance on third parties with respect to virus assay creation and product candidate testing and with respect to its clinical trials; variability of results in models and methods used to predict activity against SARS-CoV-2 variants; whether the epitope that pemivibart targets remains structurally intact; whether pemivibart, VYD2311 or any other product candidate is able to demonstrate and sustain neutralizing activity against major SARS-CoV-2 variants, particularly in the face of viral evolution; how long the EUA granted by the FDA for PEMGARDA will remain in effect and whether the EUA is revised or revoked by the FDA; the company&#x2019;s ability to maintain and expand sales, marketing and distribution capabilities to successfully commercialize PEMGARDA; uncertainties related to the regulatory authorization or approval process, and available development and regulatory pathways for authorization or approval of the company&#x2019;s product candidates; the ability to maintain a continued acceptable safety, tolerability and efficacy profile of any product candidate following regulatory authorization or approval; changes in the regulatory environment; changes in expected or existing competition; the complexities of manufacturing mAb therapies; the company&#x2019;s ability to leverage its INVYMAB platform approach to facilitate the rapid, serial generation of new mAbs to address evolving viral threats; the company&#x2019;s ability to continue as a going concern; and whether the company has adequate funding to meet future operating expenses and capital expenditure requirements. Other factors that may cause the company&#x2019;s actual results to differ materially from those expressed or implied in the forward-looking statements in this press release are described under the heading &#x201c;Risk Factors&#x201d; in the company&#x2019;s Annual Report on Form 10-K for the year ended December 31, 2023 and the company&#x2019;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, each filed with the Securities and Exchange Commission (SEC), and in the company&#x2019;s other filings with the SEC, and in its</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;min-width:fit-content;"> </font></p>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;min-width:fit-content;">future reports to be filed with the SEC and available at www.sec.gov. Forward-looking statements contained in this press release are made as of this date, and Invivyd undertakes no duty to update such information whether as a result of new information, future events or otherwise, except as required under applicable law.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;min-width:fit-content;">This press release contains hyperlinks to information that is not deemed to be incorporated by reference in this press release.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Aptos',sans-serif;min-width:fit-content;">Contacts:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Aptos',sans-serif;min-width:fit-content;">Media Relations</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;min-width:fit-content;">(781) 208-0160</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;min-width:fit-content;">media@invivyd.com</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Aptos',sans-serif;min-width:fit-content;">Investor Relations</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;min-width:fit-content;">(781) 208-0160</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;min-width:fit-content;">investors@invivyd.com</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>img59752938_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img59752938_0.jpg
M_]C_X  02D9)1@ ! @$"6 )8  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
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M  ,!  ,! 0$!          D*"P@%!@<$ @,! 0$  @(# 0$
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MRIY=F]UE])N5*A<U::;UM0G**;PP6+2TX(S(O:BI<:/OHCCD
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M1FI[.A23PDMF*]\DGC\)';1KNI+9DDM!9]&IS)
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M0T53W[W&S#<G-7;U=JIE=1MT*V&B<?@RPT*I%:)1T8^%'HM'=P\D>&
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MI2'&UI4DS(R,5!J4ZE&I*C5BXU82:DFL&FG@TUP-/0T2>O2M1Y<<
M      '%G<E^CKY\?,LY3?F-SH3NZWM-EWI]OY6!PJ>+ES/O&1T+G$6
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M&FD?54[(69?YQC1';)E.FTSRFM>-&;]V=/\ Q/<1F6LM<.Z71!HLRP
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M[U1NCV>[BV>Y67;4]BIGE:/UU5+4M?5T\=*A'A>ASDMJ6A1C&-OP?\$O\/\
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MT=? ?YEG%G\QN"BF.]/M-F/I]QY69*4_%QYEWCM,01S
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MQ:^MAMM-I+ZB$$0I;6K5+BM.XK-RK3DY2;UMR>+;YV\252P6"U'L(Z@
M        &,WLC[XF>_9IE/U\G"\=K_"T_NX]Y$2]9Z6,@^     &LAVG/HS^
M"WS8=1_)*O%.=\?:K,/2ZGSF2=+Q<>8D('FCL             #/P]J?XKGJ
M[F1KSDY1U_DXUR;P!N!D<EEE9H^ZCJ"/4XS9N27$$;$?X3P"?CWD)5X5ON0Y
M2R\7A6960[(LW\[R.KE-1_6VE3&/W=3&2]R:GCQ8HP;F.$]K@95V&VS&
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MXU"[0]P:VZ=YYW8J=3(:LNA)Z73D_P!7-_,D_"6C3)/&5@:]-:@
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M4]/$9'X=-=L.<]1EM#)*3^LN)]9/Y%/P4^24WBN6!E6T,9.?$7QA7DS0
M          #&;V1]\3/?LTRGZ^3A>.U_A:?W<>\B)>L]+&0?     #60[3GT
M9_!;YL.H_DE7BG.^/M5F'I=3YS).EXN/,2$#S1V             !"/[0;Q6
M/D[VT]MSJB F9FW'>1#Y$XH;<=*Y2H.!PK*/L.&E\E)?3'<UI<6TGRD^-+TJ
M''ZH-24*1[WLVS?U3O51C-X6]RG1ESS:V'_?45R)LZ:\=JF^-:3,?%KB.
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M4,>BI-:,<->!2*^=G*\JRR]3C8NI+JU-IS4,7LJ36C'##'#\NL]Q&,8H
M!D==R7Z13GQ\]/E-^?+.A<W=;V9R[T"W\E BZGC)<[[YQ8)XX
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M\9'0N<18    !;B]D@_O%<N?Q*X1\N71ICMF_IEE]_/YAE6OA/F+VPKV9H
M            !2F]K-XJDS/XW\T,?K%DF:Q8\>=FSF&D)83(B':9UJJ7()E!
M+7*E1WLEC/2'3/\ JXT1HCZ)0D;W[&\XQC=9%4>K"M37N0J+YC2Y9,P[J.J?
M<*8 WH8@    !V%V_P#DG,XA<T..'(IB0_'KM;[/H9>6E'<4T]+U[>K<Q;9%
M:VM/4DKL\#O+%A)J)224X1FE1%T.#WDRN.=9%=98UC*K2>SR372@^Y-19SIR
MV)J7*:Z+#[,EEF3&>:D1Y#3;\>0PXAUE]EU!.-/,NMFI#K3J%$I*DF9*(^I"
MF+33P>AHE#_4?                >J9YFV-ZUP?,]C9C8(J,0P#%,BS;*K5
MTO$W68WBM1,O;RP<(NAFB%60'7#+^9([K>A5NKB%K06U6J3C&*XY2:27=;/C
M:2Q>HR N2^\\EY-<@]S\@LN\:+_<.R<MSZ7#4^N2BH8R&XE3JS'XCKGNCKL<
MJG&($4O_ $(\9"?J$+JY5E]+*LMH9;1\70I1@GQ[*P<N>3Q;Y61<I.4G)ZV?
M#Q('$     U.NR;Q0_5 [<6@,%M*WX-SS85*K>6SFW(_JLWXY;48AW<>NM&#
M4LT6F*86W3T;_I/JNKZ^CKT*HF_F<>N]Z+FX@\;>E+JJ?%LT\5BN24MJ:^42
M5&.S32X25X>/.T               QF]D??$SW[-,I^ODX7CM?X6G]W'O(B7
MK/2QD'P     UD.TY]&?P6^;#J/Y)5XISOC[59AZ74^<R3I>+CS$A \T=@
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M??1YFM#3*E[V;JWFZV8NUK8SM)XNE4PP4X\3X%./OH\&AK0TSM4>5/+
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MZ;X%]I/#3L)ZEH<WH6"4I1NSX+@V(ZSP_'<!P.@K<7P_$ZN-3T%#4QT1H-?
MC),DH;0DNKCSSBE./.K-3K[RUN.*4M:E'56[N[F_N9WEY.52YJ2<I2;Q;;_M
M@EJ2T+053O+NYO[J=Y>3E4NJDG*4F\6V_P"V"6I+!+0CC+GYSNP7A/K%RR?5
M"R#;V6PIS&K\!6I;GKTUI),KR7)$,/QWX.'TS[B3?42VWICG2.P9*-QQGU.Y
MVZ-WO5?["QAEM-KK:G$O@QUXSEP<$5TGP)^GW.W1N]ZK_86,,LIM=;4XE\&.
MM.<EJX(KI/@3I#[1V;G6Z,_RC9^R\@FY5F^862K.]NIRD$X^]Y3<:-&CL-$W
M&@UM="8:C1(S*$,18S2&FTI0A*2M9E^7V>5V=.PL(*G:4HX1BO=;?"VWBVWI
M;;;TLMAE]G9Y594\OL(*G:4HX1BO=;?"VWBVWI;;;TL\'B6(9+GN3T.%X916
M62Y7D]I$I:"AJ(ZY=E:VDYU+$6'$8;ZFMQQQ7I,^B4I(U*,DD9EVW-S;V="=
MU=3C3MZ<7*4F\$DM;;.ZYO;>SH3NKJ:IV].+E*3T)):VRZMVWNWAB_"W U7N
M3MU.2[_S*$W\<\MCM>L1\9K74QWTX#B,EXB6BFAR&B7,E)2VY9RB):R\EJ,V
MU5G?C?2OO3>=3;[5/)J3Z$'KD_M)KX37@K2HK0M+DW5??K?:XWJO.IH;5/)J
M3Z$'H<G]I-?":\%:5!:%I<FY-QX,\"      !D==R7Z13GQ\]/E-^?+.A<W=
M;V9R[T"W\E BZGC)<[[YQ8)XX     $[?#3V>WF?SBXVZXY1ZGV;QAQ[7^S_
M (X? %/L3,]K5.8P_B5GN4:[M?ABOQK2V6TL?UBZQ*2['\FPD>.*MM2_+<-3
M:->YYVE9%D&:5<HO*5W*YH[.+A&FXO:A&:P<JL7JDL<8K3CP:3NA0G..TFL&
M=/?PGO<4_#/PL_\ F+O+_P"W,1/XQ;L_87_]RE_[YS\UJ<:_+_P'\)[W%/PS
M\+/_ )B[R_\ MS#\8MV?L+_^Y2_]\>:U.-?E_P" _A/>XI^&?A9_\Q=Y?_;F
M'XQ;L_87_P#<I?\ OCS6IQK\O_ ?PGO<4_#/PL_^8N\O_MS#\8MV?L+_ /N4
MO_?'FM3C7Y?^!^6;[*)W&8L5^0QMGAM9/-(-;<&%L?<K<J4HC(O*878\?H$%
M*SZ__P#1YM/H^J/L>V'=AO!T;Y+C<*7YJS?Y#YYK4XU_;N'..Q/9M^Z[@K;[
M]-IS!-I1XWC4X[KO<. >8II"5*4ZQ SRVP6TE=23T)MIA;RC,B)!B4MNU'<^
MX:4Z]2BW\.G/OP4U^7 ^.WJK@Q(L=X\.>5W&E;GW?>.FY=2Q&W6V476;Z^R6
MFQF6XZXEELJW*GZ_XMVJ5O+)!*C2W4FL_#U\7H'KLOSS)\U_IUU0K2XH3BY=
MV..TNZCJE"4?"31S8)4X@       !_JP^]&>9DQGG8\B.ZV^P^PXMIYAYI9.
M-/,NMFE;;K:TDI*DF1D9=2'QI-8/2F#08[ ?>:5RZQ>LX?\ );(DKY-8'0+^
MY]F]O,,Y.^,'H(*%2$V4N;*=D6.V,6@,+>L#+^LMJYLYW13S,Y8K;VC[C>I:
MSSO*H_Z54ETX)>)FWP):J<GHC\&71U.)G4*VWT9>%WRSV-3F2   &+.+UD0
M     !KB]MKZ.O@/\RSBS^8W!13'>GVFS'T^X\K,E*?BX\R[QVF((Y@
M           0L^T._0\\OOR ?O0Z3'N^S3VVLOVWD*ITU_%/N=\S#1; C@
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M[O5-VL[JY>\7:OITI/WU.6K3PN.F,N58ZFB3I3ZR&UP\)(T/,'8
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MRGU/O5=48K"A5EUT/DU.D\.13VHKY))49;5-/AU$M(\:=H
M! '[2-RH1QZ[<66Z\I[!<3.>4>256F*9$5XVIC&'>G*-G62D]4D[5R<6I_@.
M2GJ9];YOT&7B,MC=EV4>L]Z(7,UC;VD75?%M>#37/M/;7R&=%Q+9IX<+,V,6
ME(\     D.[4_%)?,[GQQUT?-KEV&&R\UC9KL]/EDJ,C66O4*R[,(LQQ3;S<
M=&00*HJEE:TJ3ZW8,IZ'XN@\SOAG'J+=RZOXO"NJ>S3^\GT8X<S>T^2+.RE'
M;FEP&L0E*4)2A"4H0A))0A)$E*4I+HE*4ET)*4D70B+Z@IT29_0
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MYE8@R)73P*\IOME/KG=BZM(K&O&GUD./;I]))<LDG']([*4MFHGP&K(*?DF
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MOO%N_?;N9A*QO%C#2Z<TNC4CP27$_A1QQB]&E8-]1#SY @
M%9_NV=S8K'XR<4>/%^A=?T=I]R;)HI[A*ENI<6U8ZVQB=$6AM4)))\JZE-K6
ME_Q+A)Z(3(\S?'9QN$X=7O%G4.GX5"E):N*K-/AX8+@T3^#AO#L\W'ZMPW@S
MF'3\*C2DM7%4DGP\,%P>%KV<*WG@/^G_ !#>)NWK&=O\%>#^P.:NTV<:IDRZ
M+6V-2*^;M'8'E(]7QVFD..*1651O-N,3<MO6HSK<"/X5I2:5/ND3+2S'D][M
M[+/=7+W7JX3OJB:I4^&4EPOBA'%.3[BTM'EMZ][+3=BP=>IA.^FFJ5/AE+C?
M%".*VGW%I:+O>H=1X!HG7.+ZJUA01\;PK$8'J-36L*4ZZM3CKDF=8V$MPS?L
M+:UG/.2)4APS<??<4M1]3%4,RS*\S>^J9CF$W4NJCQ;_ "))<"2P22T)+ JS
MF68WF;7M3,+^;G=5'BW^1)+@26"26A)8'PKFAS'UUPPU/)S_ # TW63VRI%7
MKS (LQF-;YED*&?,\!*63CD#'JHG$.64_P MQ$5I:4I2X^\PR[,;K;L7V].8
MJSMNA;QP=2HUBH1_/)ZHQQTO'4DVI7=G=N\WFS!6=MT:$=-2HUBH1_/)ZHQQ
MTOB2;5';>>[]D\B]FY)MC:E\_?95D<DU'U-:*VEJVEN'6X[C\%3BVZNAIV7/
M+CL(,_\ TEK4MU;CB[8Y1E-CDEA#+LN@H6\%W9/AE)\,I<+[BP225J<IRZQR
M2PAEV7P4+>"[LGPRD^&4N%]Q8))+YI44MOD%M64-#63[J[NI\2JJ*BJB/S[.
MTLY[[<6#7U\&*AV3,FS)+J6VFFTJ6M:B2DC,QGU:M.C3E6K24*4$W*3:226E
MMMZ$DM+;,ZI<TZ-.56K*,:44VVW@DEI;;>A)+6RXSVONV]5\3L6C[7VC!C67
M(?,*A*)3+R8<N+JJDG(\3N+4<EE<EI[(9K2B3;6#3AI5_P E8/R4NNRJQ[_[
M\U-X[AY=E[<<DI2T:TZTE[^2T=%>\BU\9Z<%&MF_F^]3>*N\OL&XY-3EHUIU
M9+W\EHZ*]Y%_*>G!1EY&M37         9'7<E^D4Y\?/3Y3?GRSH7-W6]F<N
M] M_)0(NIXR7.^^<6">.     !IY>SQ?0\\0?R__ +T.[!4_M+]MKW]CY"D2
M-#Q2[O?)IAX0[@        _'85\"V@RZRT@P[*ML([L2?7V$9F9!FQ)"#;?B
MRXDA#C$F.\VHTK0M*DJ2?0R,ARC*4)*<&U)/%-:&N8$*G,KL =N_EO%L[>IU
MDSQMV=*1)=C; T%#K,0@/V#IK>0_DNMD1%:_OV'IBS<EN-0H-I)(U%Z\V9DH
MO=Y'VC[S9,U"=7SJT7O*S<GA\6>.VM&K2XKX+.F="G/@P?(4G.XSV5>7_;K?
MG9;DU,QN#C_ZZIBLWQKB!.>I:]EV0IF SLG&'%2KG6EI)2IHO%)7*IUOO)8C
M64EWQ)+?&[&_>2;S)4:4NHS+#31FUB^/8EH4US82P6+BD8=2C.GIUQXR($>V
M.H      #V[ <]S+5F;XELG7>1VF(9W@F0U.5XAE%+(.-:T.0T<UFPJK2"]T
M4E+\26PE1$I*D+(O"I*DF9'T7-M0O+>=K<Q4[>I%QE%ZG%K!I]P^IM/%:S4T
M[3G<0QGN0\3\;VVA-=3[:Q)]K!-[89!4I#=!L&OA,O*N*N,[_7IQ3-Z]Q%G6
MJZN(9)UZ$;KKT-]0J-OCNS5W7SB=EIE9SZ=*3X8-ZG\:#Z,N/1+!*2)*E452
M&/#PDFP\H=@ &+.+UD0      !KB]MKZ.O@/\RSBS^8W!13'>GVFS'T^X\K,
ME*?BX\R[QVF((Y@                0L^T._0\\OOR ?O0Z3'N^S3VVLOVW
MD*ITU_%/N=\S#1; C@    "R87!M[E/[/EJ3DG@5 TYM?A7LO?[]V<1"W+#+
M]#W>;OY-GK*TM,)4[(P&?9-7;!.N&U&KHMH;?5V223U;_N!91VDULKN)?Y._
MI4<,=4:RALP_OI.+XY.' C(V-J@I+6L?<*V8VD8X    !.1V$^XO^HAS$K,<
MSZ\57\=^1SM)KC:BIDMJ/3XC?G-=;UWM.6J0;;$>/B5O9O1+)Y3K;;-+9S'U
M$XY'90-?]HN['^X<D=6VCCF=KC.GAKDL.G3_ $DDXKAE&*T)L[J%38G@_!9I
MH"JA(@         '%G<E^CKY\?,LY3?F-SH3NZWM-EWI]OY6!PJ>+ES/O&1T
M+G$6     6XO9(/[Q7+G\2N$?+ET:8[9OZ99??S^895KX3YB]L*]F:
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M&1DG0G;'G&U6MLBI/HP775.=XQIKG2VWS21F6L=#F^8N2C1YE@
M      8S>R/OB9[]FF4_7R<+QVO\+3^[CWD1+UGI8R#X     :R':<^C/X+?
M-AU'\DJ\4YWQ]JLP]+J?.9)TO%QYB0@>:.P               BM[TW%0^7O
M;CY#Z^JZUJQSK"<=+=6LTFPF1-3F>J4O9*NOJ$J+HBVRS$VK6B95U21?"I]5
M$DS,>OW$SCU+O/;7,WA;U)=54XMFIT<7R1ELS?R3JK1VZ;7#K,KD6\(T
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MQ?"G[J>*:33163.,HO,COIV%]'"K'2FO!E%ZI1?"G[J>*:331]T$018
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MY<DA6[M#W]><U)9+D\_](B^G-?KI)\#^S3PPU;3TZ5LF@M^]]Y9O.6497/\
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MVVOHZ^ _S+.+/YC<%%,=Z?:;,?3[CRLR4I^+CS+O':8@CF
M  !"S[0[]#SR^_(!^]#I,>[[-/;:R_;>0JG37\4^YWS,-%L".     -$/V7E
MNKRGM>YECEPF%D%0KDEM[&[BDGFS902K[3!]92IU%80'C>91%L(=P;KD9Q))
M<;E>(TF3G4ZS]K3G1WMA5AC&?FM.2:T/%3J8-/D:U\G(9]MII]TIT=V?@C9]
MO?FGLK2T6'8_<LNWRV'HN[G&M_X7U9E$F4[4P%SE$DYMIA=BQ*HISBDMK>DU
MRGR0EMYHU;NW-WAAO+D5*^DUYY'H54N"I'6\.!26$UQ*6&M,Q*L.KFUP<!&F
M/5'6     :1_L\?<7_7,XCQ=.;&O_A#D%Q>A4^%9$Y/?\=KFNKO)5#UOG:UN
M?UL^;%@PU4MJZ:G7E3(#<N0LEST$=7.TO=CU'G3OK6.&6W;<HX:HU-<X<BQ>
MU'@P>"\$D*%3;A@_"18)&MSO        #BSN2_1U\^/F6<IOS&YT)W=;VFR[
MT^W\K X5/%RYGWC(Z%SB+     +<7LD']XKES^)7"/ERZ-,=LW],LOOY_,,J
MU\)\Q>V%>S-                 J&>UB<5RR;3V@.8=!7^9;:PR>9IC84B.
MR@WW<*SQ,B_PNRGOF1*178SF-3+B-D1GUD9&7HZ=3+=/8[F_57USDE1]"M!5
M8?*AHDERRBT^:!BW4<4I\11:%@C"     .U>W1R4>XA\X.-'(,[!5;28)M&B
M;S>07C,CUME*G<.V6T:$(<-:G,$O[#P>Y5X7?"HBZI(0.\^5+.L@NLMPQJ5*
M+V/EQZ4/^M(YTY;,U+E-<!IUMYMMYEQ#K+J$.M.M+2XVZVXDE(<;6DS2M"TF
M1D9&9&1BF333P>LE#^P            'H6U-DXKIO66P]N9S.3687K#",IV!
ME=@?AZQ,>Q"DFW]P^@EJ22W40(#G@3UZK7T27I,9%G:UKZ[I65NL:]6I&$5Q
MRDTE^5GQM)8O4C'XWGMS)]^[GVOO#-'5.97MS8F8;%OB\]R0W&LLPOIUZ_ B
MN.)090*XYOJ\=!)0AMAM"$I2E))*Z^7V5++;&CE]#Q-&E&"YHI+'G>&+Y2*D
MW)N3UL^5C,/@   ?LKZ^=;3X5761)$^RLI<:OKX$1E<B7-G3'D1XD2*PT2G'
MY$E]Q*$(21J4I1$7I,<92C"+G-I02Q;? EK8-<;M]\8(7#7ACQWXWL,LMVFN
M-=53&9NQUM.LSMCY"M_*]E6+#S*W4.19V=WE@XQT6YX8ZD():B21G3'>3-I9
MYGMSFC\"K5>SR071@NY!1QY24A'8@H\AV,(0Y@                8S>R/O
MB9[]FF4_7R<+QVO\+3^[CWD1+UGI8R#X     :R':<^C/X+?-AU'\DJ\4YWQ
M]JLP]+J?.9)TO%QYB0@>:.P               _E24K2I"TI6A:32M"B)25)
M47125)/J2DJ(^AD?U0!DV]T[BM^IGSWY(:)@0$5^'U.>2\LUHRPWX(;>L=A,
MLYM@T"(HFF6GOB]1WC=6^IM"6RF07DD1>'H5QMT,X]>;NVN82>-=T]F?'UD.
MC-_I-;2Y&B,JQV)N/ 1]CTIU@    %WCV3#E =GAW)7AU>6"ER<7M:KD#KR$
MZM+CATF0(KL%V6RSXS)V/ J;F!CKR&T^)LW[5Y?1"E&;F@^V3*=BO:YW36B<
M71F^6.,X=UIS7-%=S,M9:'#NER :0,L             *N7M47*A>K^'6N.,
M5#8(8R'DWGY6.41VWB4_]R[4#]1DM@P\RV9.QOA78-ACRF7%F2'FH,ILDK]V
M:-M]D.4>=YW5S:HOJK2GA'[RIC%>Y!3QXL4S&N980V>,S]!9 P0    ">GV<
MKBA^LCW'\%S:[JU3<"XO4TS>UZZ\RZ<)>85,ABFU37E*;]PQ;1\YLV+N.A1_
MUK5$^7U",:Z[3\X]5[KU+>F\+B[DJ2X]EZ:CYMA.#^6COMX[53'@6DTKQ5DD
M               #Y!O;1NNN1NL,EU+M"F1;XQDD52/-0F.FUHK1I#A5N1X[
M-D,22K+^H><-R.^2%%Z5(<2MI;C:Y/)\WOLCS"GF67SV;BF^7"2X8R2PQC+A
M7=6#2:D,KS.\RB]A?V4MFO!]R2X8R7#%\*[JP:3*0_,GAYL7AMMB=@&8MNVV
M,V)OV&O,_CP7(U-F^/)4W_7L$:WD0KRJ4^ABR@*<4Y%?Z*2;D=V.^];/=;>>
MQWIRU7MJ]FXCHJTV\94Y?GB]<9:FN*2DE8_=_>*UW@L5=6[V:RT5(8Z82_.G
MKC+A7$TTN2/!_N?[Q#TV!.]8RSMVG>YDO+DX]Q:Y#9"\_EY&W5:AV-=2DG\9
M8K,=*86 9382%$M62L)9-%5->6H[))IB.'ZVEDY=?^TC<'S7;WAR2"5KKK4H
MKP'CIJ07P/AQ7@^$NCCLZ9WYW/5!SSO*H84-=6FO>OAG%?!^$EX/A+HX[-A@
M:3-4E;_NQ]LE<M>1<J./&.NO2W7)=WN?7=-')PWNJ52)^QL6KF4^8;W5*G+J
M(T2C7U.8V@C*2:MZ=F^_RCL;NYW4PCHC0JR?<5*;_)"3^0_>FWMQM]'%0R3-
MI]%8*C4;]RG)_,;^2_>E;+P'_@D;W-O=8SL[A'S.V#PNVHSF..>L7V#7IQJ_
M9&O79CD:NRFF;6KRY<;KXV(.44I.K<KYAH4;:E+:62F'G4*\MO9NK9;U9<[6
MOA"\ABZ53#%PEQ/CA+5*/#H:TI,\[O)D-KO'8^;UL(W,=-.IPQ?%RQ?OES/6
MDR[CIS<.O]]:XQG:FL;V/D&(Y5 ;F0I+:FTRX,@B),ZFN8B''55MY42?$Q+C
M+/QLO(,O270SJ;FF5WN37U3+LP@X7--X-<#7!*+X8R6E/A17',+"ZRR[G97D
M7&O!X/B?$T^%/6GPH^G"/,,        (4.Z?W)V>/=/9:!TE<$YO3(:QKXQY
M36/QW4:EH[$O$7A61/>'/+B#U.*R9(<KHSR)BC2M48E[7[.]PWG=6.<YM'_2
M(2Z,'C]=)?X<7K>J33CJVL-B;E;HO-:D<TS*/^F0ET8O]:U_V)ZW[YK9^%A4
MHDO29LF1,F2'Y<R6^[)ERY+BWY,F2^XIU^1(?=4MUY]YU9J6M1FI2C,S/J+)
MQC&$5"&"BE@DM"27 C>T9J*48X**6"2X#[IQLXV[+Y3;5H-4:RJERK&S>;D7
MEX^PY\!X=C;<AEJTRG(I2"Z1JRM;>+HDC\Z2\I##*5O.MH5#Y]GMAN[ET\RS
M"6$(K",5X4Y<$(KA;]Q+%O!)LC<WSNTR6QE?7DL(1U+AG+@C%<;]Q+%O!)EW
M_BIQ;UKQ&U-4:LUU%-\VS*QRO+)L:.S?9MDSS:4S;ZX6P1DDNA$U$C$I:(<1
M"&DJ4:5+74O>+>&_WES*68WSPX(03>S3AP1CC[K?OGB^15OSS.[S/[^5]>/D
MC%>#"/!%=]OA>+Y#V_?>^=;\;-89#MK:=S\$8Q0-I;;980F1;WUQ)2X57CF/
MP#<:.PN[9ULTM-^)#:$I6ZZMMAMUU&+DV37^?9A#+<NAM7$^Y&,5KE)\$5PO
MF23;2>/E>67>;WL+&RCM5I>Y%<,I/@2X?<6+:12%YA\N=D\QMKSMA9Q)5 H:
MY4RNU[@\9Y3E/A&,.R"<:@Q_0A,VYGI:;<LIZDDY,?270FV&V&&;:;L;LV&Z
M^6JRM%C6E@ZE1^%4GAK?%%:5&.J*XVY-V/W?R2TW>L5:6JQJO!U)\,Y<;XDO
M>QU)<;;;Y/\ !_N?[Q#TF!.]8RT!VGNV8G"6,?Y1\@Z!MS,9D=FUU+KN[KW$
MN86RXI+L+.LE@S$(\.626B)RLBK095K2TR5_Z8ILH=?>T??YW<I[O9+-^:IX
M5JL7XSCIQ:]XO?O'I/H^#CM:9WYWSE<N>2Y5-^;IX5:B?A\<(M>]^$_?/1X.
M.U8.&E35(           &1UW)?I%.?'ST^4WY\LZ%S=UO9G+O0+?R4"+J>,E
MSOOG%@GC@     :>7L\7T//$'\O_ .]#NP5/[2_;:]_8^0I$C0\4N[WR:8>$
M.X             /Y4E*TJ0M*5H6DTK0HB4E25%T4E23ZDI*B/H9']4 9ZWM
M#O:4A<1-DHY;\?L7:K.-VY,C5$S'$Z.'Y55IO:UKZU.7%@0HR"8J-?YUY+K]
M:A!)BUM@EV"@F67(#*K*=FF^4LZM?4N93QS2A'&,F]-6FM&E\,X:I<,EA+2U
M)F#7I;+VX^"RLD-KF,      !I?^SS<U7N7';^Q+%,MNE6NV>,,R/I/,W)3J
MG+*SQ2MA)DZFR>4:R4XXF;A:453C[CCCTN?22GUF1N$*K=I60K)=Y)UJ,<+.
M[76QXE)OZR/<ETL-24DN D*$]JG@]:)V1KT[S%G%ZR(       UQ>VU]'7P'
M^99Q9_,;@HICO3[39CZ?<>5F2E/Q<>9=X[3$$<P                (6?:'
M?H>>7WY /WH=)CW?9I[;67[;R%4Z:_BGW.^9AHM@1P    !H->R=OLJ[>6ZX
MR7FE2&N9V?ONQR<0;S3,C1_'IN.\XT1^-#3ZXSB4*,B)1MJ(NOA/I6WMB3_W
M+0?!YC#RM8SK7Q;Y_P R.B?:&>WW^N7POLMGX+2>O[VXL,7FRL/3$;\5CD^O
M518[VUL'0E"5NRWWZ.J:N(#*4./NV%2W&9\/K;GBC.S7>3U'GJM+B6&7WF$)
M8ZHS_5SY-+V6]6S)M^"CE7I[<,5X2,UP6E(\     [L[;W-S+^WYRWUER)QS
MU^?CM7/+&]K8G!<0E6;ZGR"1%9S''4H><:CKLFH[#<^L4ZI+;-M"BN+ZH0I)
M^>WHR"AO)DM7+*N"JM;5.3]Y47@RYN"7'%M'.G-PFI&K_@6=8EL_!\/V1@-[
M R?!\^QFCS'$,CJW2?KKS&\DK8UO2VL)TNGCCSJ^6VXGJ1&1*Z&1'U(4[N+>
MM:7$[6YBX7%.;C*+UJ47@T^9HDTTUBM1[:.D^@      <6=R7Z.OGQ\RSE-^
M8W.A.[K>TV7>GV_E8'"IXN7,^\9'0N<18    !;B]D@_O%<N?Q*X1\N71ICM
MF_IEE]_/YAE6OA/F+VPKV9H                '*?.3C96<O^(O(+C;9$PE
M>U=;W=+029)H3&K<WKR:R#7UU(-;;J?(H\ZIZZ8OT=32P?0TGT44QD&:3R7.
MK;-(?J:J;Y8/1-=V#DNZ<9QVXN/&9$EO4V=!:V=%=0)57<TMA-J;:LG,KCS:
MZSKI+L.? F1W"2XQ*B2F5MN(41&E:3(_20NA"<*D%4IM.$DFFM33TIKG(H\<
M.8     -4'LH\H?UL>VUQPSFQLOA'-,&QC[B>Q%NR?6YY99J;RL69GVSYF:E
MVF48G'J[IWQ>Z,[,C/ZHJ)OYE/J;>FZMXK"A4GUL.!;-3I8+DC+:C^B25&6U
M33X25<>/.T           "NG[37RC3HWMZ.Z>IK-,/-.5&=5&O6([$HH]DC7
MF).QLWV):1D$9./P''*^II9B2+H;%[X5>A7IV;V4Y1ZPWE\]FL:%G3<^3;ET
M(+GTRDN6!CW$MFGAPLSDQ9XP     ":WL <3OUJ>Y/J%VXK_ %W >/J)/(C-
MO-:\49US )U<C *U:G6'H;ZY^S;6G6[&<],BOCR_"7N%&7@^T?.?5&ZU90>%
MS<_4P_33VWQZ*:EIX&T=U".U47$M)IUBJ!(@                 !C-[(^^
M)GOV:93]?)PO':_PM/[N/>1$O6>EC(/@    !K(=ISZ,_@M\V'4?R2KQ3G?'
MVJS#TNI\YDG2\7'F)"!YH[                 *8'M9O%4WH/&_FAC]8@U0
MGK'CSLV<PTM3ZF)96F=:JER$LH-"(L9]G)8STATR_K)$1HC,U(2-Y]C><82N
MLBJ/7A6IKFPA47S&ER29B74=4^X4IAO@PP    "47LS<H"XE]Q[C7L>QL$U^
M&9/F#>H-BN/+4W!3AFV$%ALFRLU(-+GJ&*W5C!NU>'J?BK$^Y675"O([\Y3Z
MYW7NK6*QKPAUD./:I]+!<LDG']([*,MFHGP&JF*A$F             &9A[0
MWRI/DQW*]ITE3/3,PCC= @<>L8)F0ER.NVP^5/L=DRULM))EN>C9-U:5ZU^)
M:W(]<P2E%X4MMVK[-,H]5;K4:DUA<73=:7-+!07-L*+YY/G(ZO+:J/B6@@V&
MP#I     -%#V8?B:>C>!UGOG(*OU+-N6&:OY8P\\RMB<C56 .6.):\AR6GFD
M.$B9<+O[>.X2C;?@V\=:?1Z3K+VL9SZPWB674WC;V=/9Y.LGA*;[BV(OB<69
M]M'9ACPLLD#5QD                 <]\F^,^L^5VJK?56SJ];L"2X5EC]]
M!)M%[A^31X\ABNR2AD.)4EN9$3)6AQM9*9DQW'&74J0LR$WD&?W^[F8QS'+Y
M=-:)1?@S@VL8R7$\->M-)K2B4R?.+S)+V-[9O"2T2B]4H\,9<C]U/!K2BD1R
M<XR;,XH[5M]6;,K";EQB5/QS(8:%G19EC+TAYFOR2BD++JN+*-A2'65='HLA
M"V72):#%M=W\_P OWDRZ.8V$NB]$HOPH3PTQDN-<#U-8-:&6'RC.[/.K.-Y:
M2T/1*+UQEPQ?_'4UI1SZTIUEQMYDULO,K0ZTZTHVW&G&U$M#C:T&2D+0HB,C
M(R,C(3346L'I3)-U$U@]1:[[5_<H:W?5U7'C>MTS'W%1U[,3!LOM)B_,VO4P
M65$J#8R)2C\W/ZN,T2G#-9KM6"-XD^<V\;E<>T7<)Y14EGF3P;RN<L:D$O$M
M\*2_5MZO@/1J:PTIOGNIZOJ2S3+8_P"0D\9Q7ZMOA6'O'_TO1J:PG!4E*DFE
M1$I*B-*DJ(C2I)ET,C(_09&0U&:\*N'=9[9R=:/WG)KC[CS3.MI"CL-HZ_J6
M#+XB6$J492,OQJ TGPHPF:Z^DYD1HNE0Z9NMEZBI285A>SG?[S]0R#.IXWZT
M4:C_ %B2T0D_M%[V3\-:'T_#W)N7O@[N,<HS2;=VM%.;?AKX,G\-<#]\M#Z7
MA0'^ _\ U2_WO\@W,;*ZU$@G;^YW9GPNV,1O)E9#IC,K& WLK"V_"M]MILTQ
MDYABI.J;;C9531%G_5FM#%DPGU=XT&3$B/XK?3<ZUWJL=&$,UI1?53X./8GQ
MPD^'7%])8Z5+R^\^[UMO!:<$<PII]7/_ +9<<6^[%Z5PIW2=>["PO:V%X[L/
M7F15V58;E5<U:45Y5NFY&F1G#4A:%H6E#\2;$?0MF1'>0V_&?;6TZA#B%)*J
M=]8W>6W<[&^A*G=4Y82B]:?YTUI36*:::;3- 75K<65Q*UNHN%>#P:?!_P 4
M]::T-:5H/<QBG0     1.]R_N+U7$[%G-;:RF5EUR#RRN4<5A2FYD76-)-9,
MFLLOHI)<:>NI*%]:JO=Z$X?^DOI5'0AJ3LC<'<:IO)<>?Y@I0R2G+3P.K)>\
MB_@KW\EJ\%=)MQ]KNENM+.J_G=XG'*X/3P.HU[U/B^%)<RTZ53RM[2VR"ULK
MV]L9US=W,^7:6]O:2GY]E:64]]R5.L+"=*6[)F39DEU3CKKBE+6M1F9F9BS]
M*E2H4XT:,5"E"*48I))):$DEH22U(WM3=.E!4Z:4:<4DDM"26A)):DN!'T32
MND]B\@MD8YJK5U Y?9;DLDVX[1J-BOK(+)$Y87EW/-M;=925,;J[(?41]$D2
M4)6XI"%8.;9M8Y)85,QS&>Q;4UW6^",5PR;T)>[@DV8V89I:Y9:3O+R6S0@N
MZWP)+A;X%^;27:>%O#;77#35D?#,39:M,QO6J^PV7GCS1)LLOR&,PXE*6S4D
MEPL;IERGFZR$7N6&G%K7XY#S[KE3=Z]Z;[>G,7=W/1M88JE3X(1??E+!.4N%
MX)8122KWO#G]WO!>NXKO9MXXJG#@C%]^3P6T^'5J22Z!VIM+!M+8!D^SMCWT
M3',/Q*M>LK6QE.(2I9(+PQJ^ PI:%S[>TE*1'B1F^KLF0XAM!&I1$(7+LNO,
MUO:>7V$'4NJLL$E^5OBBEI;>A)-LB[.SN,PN86EK%SKS>"7YWQ):V^!:2E!S
MHYM9[S1V>[D%D4_']98V](B:TUZN6EV/1UR_"V]<VR6.D6;EEX39.2WR\9,H
M\,=I9M-)4JV&Z&Z5GNKEZH0PGF%1)U:F&F3^#''2H1U)</A-8LL%NWD-KN_9
M]5#"5Y/34GQOB7"HK@7#K>EG#WA/_P!0>NT'HNL18G[4';..W=QWE-R$QYYF
MLC/Q;O3NNKF&A*;E:$HD5NQ,FA/^)WX*9=,G:B(XA!R5I3,7U8\@G]']I&_R
MI*>[N233J-.->K%^#P.E!\?!.2U>"NECAJW?7?#84\FRN?3:PJS3U<<(OCX)
M/@\'7CA9:&A#48             9'7<E^D4Y\?/3Y3?GRSH7-W6]F<N] M_)
M0(NIXR7.^^<6">.     !IY>SQ?0\\0?R_\ [T.[!4_M+]MKW]CY"D2-#Q2[
MO?)IAX0[@              #XIR.T#KGE+HW9_'W;%4FWP+:N)V>*W;:6XRY
MU<J6V3E7D5*Y+8DL0\CQ>W:8L:V0;:_5IT5ITB,T]!GY7F-UE&84LRLWLW-&
M:DN)X:XOCC)8QDN%-H^2BI1<7J9DD\GN/>=\4>06W..FRH_D9EJ/-;;$K*0A
MAR/%NH<9:9-!E%8T\:GBI<NQV5$M()K]VJ',:4?0S,A<O*<RM\XRVCF=J_J*
MU-27(^&+Y8RQB^5,BI1<9.+UH^$"1/@    !8@]F@Y5/:%[AE?J*WM/4\%Y5
MXC9:UL&'W740&]@8W'FYAK.T<;;627+%Z9"GT<3Q)61+OE%[DE&M.L^U7)UF
M.[3O8+&XLYJ:X]B6$:BYM*F_D'?;RV:F' S1X%8"0,6<7K(@      #7%[;7
MT=? ?YEG%G\QN"BF.]/M-F/I]QY69*4_%QYEWCM,01S
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M4H]&ZKZA&-)=LF4[=M:YW372IR=&;^++&4.XFIKGFC+M9:7#NEXD:!,P
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MBGAM^(^J23OOL=SISI7.05GIA]=3^2VHU%S*6PTN.4F8=U#2IKF*;@W@8@
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MTRR^_G\PRK7PGS%[85[,T                  *NOM4'%<MH\-]><G:.O\
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MUGI8R#X     :R':<^C/X+?-AU'\DJ\4YWQ]JLP]+J?.9)TO%QYB0@>:.P
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M> QJ3M=SGS/)*>44WA6NZF,ONZ>$G[L]C#C2DC)MHXSVN!&@>*WF<
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M*/4O:KNQZRRQ9Y:1QO;2/3PURHZW_P"F^E\ESY#)MZFS+8>I]\T%16XS@
M #BSN2_1U\^/F6<IOS&YT)W=;VFR[T^W\K X5/%RYGWC(Z%SB+     +<7LD
M']XKES^)7"/ERZ-,=LW],LOOY_,,JU\)\Q>V%>S-                  #X
MSR+TIC7)#0NX]!9>?EXYN'6V8:\LY:642'JM&4T<RJCW<-I9I2=C12Y#<R,?
M4C3(80HC(RZC.RR_JY7F-#,:'C:%6,TN/9:>#Y'J?(SY)*47%ZF8_P#L3 \E
MU9L'.M89G"^#<PUQF.3X'E==U6KU#)<0NYV/7L+Q.(:6?JMI7.M]5)2?N?21
M?4%UK6XI7EM3NZ#QH581G%\<9)23]QD4TT\'K1Z:.\^     &JGV9>4!\M.W
M#QKV-96"K',\8P]O4&Q7'EI<G*S/4ZRPZ196:D&IOU_*J2O@W2O#T+PV:?<I
M/JE-0=^<I]3;T75K%84)SZR'%LU.E@N2+;C^B2=&6U33X244>2.P
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M[)Z)2:U=:G]HV<^N-Z:^P\;:V^IAQ=#';?%IFY:>%8$C0CLTUQO233#PAW
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MSB+     +<7LD']XKES^)7"/ERZ-,=LW],LOOY_,,JU\)\Q>V%>S-
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M<>M=Z*E&F\;:T2I1XMI::CY]MN/-%$C0CLT^5Z2> :\.X
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M:D&DEI\YO;E/KK=R[R^*QK2I.4/EPZ</=E%+1P-G.G+8FI<!K/BFY*
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MX     :R':<^C/X+?-AU'\DJ\4YWQ]JLP]+J?.9)TO%QYB0@>:.P
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M.-FE:Y%2>F3=:HN18QIKF;VWSQ3,NUCKGW"[:-"F8
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M_$KA'RY=&F.V;^F67W\_F&5:^$^8O;"O9F@                   'IFQ\
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M\7@61;:[(LH=WGE3-:B^IM*6$7_Y*F,5[D%/'BQ1C7,L(;/&S/M%D3!
M+>/LG_%#XT;AWSS(R*K4Y4:KQR-IK6\R0R[ZLYG>=H8NLWLJZ0GPM_"6,83
MBPW4*-1>KY+U\/7PJ+2W;%G'4V5OD=)].M+K9KXD-$$^24FWSP,JUCBW/B+T
MXKZ9H                     &,WLC[XF>_9IE/U\G"\=K_  M/[N/>1$O6
M>EC(/@    !K(=ISZ,_@M\V'4?R2KQ3G?'VJS#TNI\YDG2\7'F)"!YH[
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M<.C##BVDMI\LF2E..Q!1X208>;.8
M 4J.YL@SYU<A3]'_ $BQS^;_ &#Q3^D6\[.\/]EV'W<_*3/?Y14PRZDN1_.9
MRIJ%L_NLZO\ J??$PK^0O]I:S^D>FS7#U7<^CU/F,S:]5]1/Y#[QH!"CIK,A
M"[ZB?%QYU#^.9OY$96-Q=C']=NO1/\2!Z'=V6S=3?_C_ #HJ[>6?\Q?[Q?\
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M&R1"!WER.AO%DU;*ZV"E..,)?!J1TPE[NA\<6UPG.G-PFI(UC=;[$PW;FO\
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ME%0GTJ/JHZ@;[YSZ\WFN;N#QMXSZNGQ;%/HIKDD\9_I$G2CL4TN$D^'DSL
M                    QF]D??$SW[-,I^ODX7CM?X6G]W'O(B7K/2QD'P
M   UD.TY]&?P6^;#J/Y)5XISOC[59AZ74^<R3I>+CS$A \T=@
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M[(D2'7'WWWW%NO/O.K-QUYYUPU+<=<6HU*4HS,S/J8N:DDL%H2(L_P A]
M 2Q=DGBA^M[W'] X3:U:;3 ]<W*]Z[.:>9:E0CP_5<B%<PZ^TBO>XDU.59P]
M34DE'0^K5F9_4(QXW?W./4NZ]S7@\+BK'JJ?'M5,4VN6,-J2^2=M&.W42X%I
M-385&)(                                   I7=S0B_7IY">CK_P X
ML<^0>*"WW9TO_P 78?=S\K,]EEL\+&FN1]]G*NH2+[K.K_1_VB85_/\ [2U@
M]-FJ_P!+N?1ZGS&95:I]5+Y+[Q?[%&SP9"+WT/[O6HO1U_MF;^1&5C<?8O\
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MDE74R,SN5NE0\VW8R^D]#5I2;YY04G^5D74>-27.<)#T)P     .YON02/\
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MQ)0M'ONS;./5.]-&,WA;W*=&7%C/#8?_ *BBL>!-G37CM4WQK29D8M:1P
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M5WTSCU'NU=7L'A<.&Q3X]NIT4URQQ<^:+.RE#;J)<!JWBGQ)@
M           !C-[(^^)GOV:93]?)PO':_P +3^[CWD1+UGI8R#X     :R':
M<^C/X+?-AU'\DJ\4YWQ]JLP]+J?.9)TO%QYB0@>:.P
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MRZFI/Y,$FOELS;:.$7+A9;*&G#*
M  *6G<R+_OS\@_3_ .\6._(3%1<#LZ6.Y=A]W/RDSTEE/"U@N1]]G*VHB_M8
MUAZ?^T/"OY/^LE8/39JO]+N?1ZGS&=]2I]7+F?>+^@HR>4(2>^:77CWJ/T]/
M[96_D1E8W)V+?UZ[]$_Q($EEDMFM+Y/YT5?NG_"_Q"R.!.=86YNSA_<JI/Y?
M[1,^_P!?B"J_:VL-\)^CTN\SS^8O&Y;Y$2HC61@@
M    &1UW)?I%.?'ST^4WY\LZ%S=UO9G+O0+?R4"+J>,ESOOG%@GC@     :>
M7L\7T//$'\O_ .]#NP5/[2_;:]_8^0I$C0\4N[WR:8>$.X
M  #UG-<LI\!PW+<ZR*0F)C^%XS?99>RE*0A,:GQRJE7%G(4M9I0E+,*&M1F9
MD1=/2.VA1G<5X6])8U*DU%<\G@ORL-X+$QL\TRJSSK,<LS>Z4E=QF.37V56R
MTDDDKL\AM)5O/4DD(;0252IBS+HE)?S$7U!>"A1A;T(6]/P(045S16"[Q$-X
MO$]9'<     "TA^K([_"P?=*^#U^=^M[^LW_ )L+S?*^/GZI?PAY?E^M^#U#
M^7_CO)_K.OJPU'ZV7XN^:XZ/,NHX?@><8<6ON8\ID[/^6QY<?S%6\;<,8
M   #7%[;7T=? ?YEG%G\QN"BF.]/M-F/I]QY69*4_%QYEWCM,01S
M         A9]H=^AYY??D _>ATF/=]FGMM9?MO(53IK^*?<[YF&BV!'
M%X#V1'[W?.3[--$_6/: T%VT?Q67_=U>_3,RUU2[A<8&D3+       KY>T1=
MN_\ 7&XA/[EUY0(G[\XMQ;G-Z(H4?K;9CJM<=$K9.#EY#2I%E*A0X#=U5LGY
MBRE07H\=*5SW#5LGLSWF]1YTK&YEAEUVU!XZHU/>3Y,6]F3XFF_!1T5Z>W#%
M>$C-T%HB/     /L/'[>6P.,^[-8[\U9:*J,^U1F%1F&.RC-SU:0_6OD<NGM
M&FEMJET>05KCT"PCF9)DPI+K2O<K,8.99?;9K85<NNUM6U:#C+NZFN)IX-/@
M:3/L9.+VEK1K5\2.3& <Q..&H^26M)"7,6VIB4.\* ITGI6.7[#CU7EN'V3A
M(;2JUP_*8$RLDJ2GRUO15+;-3:DJ.FN<Y5<Y)FE;*[I?749M8_"6N,ER2BU)
M<C)2,E.*DM3/)\J*V)<\8>1U/8-J=@6NAMOULUI+BVE.1)VOLABR6TNMFEQM
M2V75$2DF1EUZEZ1QRB<J>;6LX^$KBFUSJ<1+P7S&/ +M$4     6XO9(/[Q7
M+G\2N$?+ET:8[9OZ99??S^895KX3YB]L*]F:                     !XZ
MWJ:R_J;.BNH$6TIKJNFU-M63F42(5C66,9V'/@3([A&V_%F17EMN(41DI"C(
M_08Y0G.G-5*;:G%IIK6FM*:Y@9$G./C99\0.77(+C;9D^I&JMD7=)029)K5)
MLL)GFUD&OKJ0:VVC\^\P6WKIB_1T)3Y]#470SNCN_FD,[R6VS2&NM23?)-:)
MKN34EW"*G'8FX\1RF)@X@    &LGVK>2_P"MOV_.+V[)EDNURBUUG58GL&8^
MK_3).Q]<./Z_SJ?+;-*%,+NLCQM^P;29>F/+;4DU)4E1TXWORKU+O)=V$5A1
M55R@N#8GTX)<T9)<Z9*4Y;5-2Y"04>;.8 %6OVJ?E#]S7AYK'C)26/D9!R3V
M*FXR:(S)]VYK'3RJW(9L>9&:,G&T6.P[7'G8ZW#)#A5[Z4I6:5&WMSLARGSK
M.ZN;5%]7:TL(O_R5,8K#F@IX\Z[N-<RP@H\9G]BQY@@    %Y3V3OBA\7M9<
M@.9V15OEV>Q+J+HW6LN1'\N0WAN(+A9/L*Q@R#4?K-7DN72JN(?0D^"3CCA>
MG^2O_;%G'6W=MD5)]"E'K9_*EC&"?+&.T^::,RUCH<RX(-*&6
M            &,WLC[XF>_9IE/U\G"\=K_"T_NX]Y$2]9Z6,@^     &LAVG
M/HS^"WS8=1_)*O%.=\?:K,/2ZGSF2=+Q<>8D('FCL
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M;?5Z4H_"GKT*EF<YE5SC-;C,ZOAUZLI8<2;Z,?T8X17(B4C%1BHK@.AQ&'(
M                                  I<]S O^_+R"^R+'?D)BO\ 2+@]
MG.'^RK#[N?E9DS;3PH17)^<Y8U$1?=7UC^,/"_E)6_TCT^;)>J[GT>I\QG;.
M:V'S,OVBBY D)??*+KQ\U'^.1OY$Y6-R=BO]>N_0_P#$@9MB\*C?)^<K!]"_
MP+_*+)X(D]M%N'LY_P!RRD_&'GW^OQ!57M;]L9^CTN\R)O'C6QY$2GC61B@
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MTW23:_L]WF_W%D457ECF5MA3JXZY:.A4_32TOX<9<&!'5J>Q/1X+(5![PZ0
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MO!FL\[SJYS2>.%:JW%/6H+1!=R"BNX2L([$5'B.L1#G(
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M7G9$B0ZX^^^^XMUY]YU9N.O/.N&I;CKBU&I2E&9F9]3%S4DE@M"1%G^0^@
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M*X&5UO*6V^SL73A=2?C#SW_7X@JGVN>V,_1Z7>9B5I;4\>0E,&L3J
M                  ,CKN2_2*<^/GI\IOSY9T+F[K>S.7>@6_DH$74\9+G?
M?.+!/'      T\O9XOH>>(/Y?_WH=V"I_:7[;7O['R%(D:'BEW>^33#PAW
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MZGO!GEQFDL>KG/""?!3CT8+#@>RDW\9M\)*4X;$%$[;$"<S%G%ZR(
MUQ>VU]'7P'^99Q9_,;@HICO3[39CZ?<>5F2E/Q<>9=X[3$$<P
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M4IOKRMF%[5O[AXUZU24Y<\FV\.33HY"5244DM2/I0Q3Z
M         8S>R/OB9[]FF4_7R<+QVO\ "T_NX]Y$2]9Z6,@^     &LAVG/H
MS^"WS8=1_)*O%.=\?:K,/2ZGSF2=+Q<>8D('FCL
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M)TM\Q*2DHQ<GJ1C\9/DEUF.29#E^23G;3(LJO+;)+^S?\/GV-U>3Y%G:3GO
M24^;+G2G'%="(NJA=>E2IT*4:%)84H144N))8)=Q$3KTG@QV    +5/LJO%
MMC\JMI\L,AK4O8]QRP@L5PJ2^TI)'M/;<>QJ7)U>ZII3+YT.N*^YCRT)-*VC
MNXJ^O170]0=K^<>:Y11R>D_K;JIM2^[IX/!\\W%KY+,FVCC)RXB_>*YF<
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M     UQ>VU]'7P'^99Q9_,;@HICO3[39CZ?<>5F2E/Q<>9=X[3$$<P
M          (6?:'?H>>7WY /WH=)CW?9I[;67[;R%4Z:_BGW.^9AHM@1P
M !> ]D1^]WSD^S31/UCV@-!=M'\5E_W=7OTS,M=4NX7&!I$RP
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M/,<AAE=)X5KRI@_NZ>$I>[)P7*MI&1;1QGM<"-"L5K,\
M          #&;V1]\3/?LTRGZ^3A>.U_A:?W<>\B)>L]+&0?     #60[3GT
M9_!;YL.H_DE7BG.^/M5F'I=3YS).EXN/,2$#S1V
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MU-M2?,ZCFT^)HDJ,=FFN-Z28H>(.T
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M,RU'CQVFV(\=AM#3+#+2";:99:;)*&FFD))*4I(B21="%-FVWB]+9*'^H^
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MMKZ.O@/\RSBS^8W!13'>GVFS'T^X\K,E*?BX\R[QVF((Y@
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MZ6WSDH>1'$                           8S>R/OB9[]FF4_7R<+QVO\
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M_ALAI/CK5%[L::^>VG\5F9:QUS[A=/&B3+
M              *;O<C3UYN;\^R#'OY3_P!A\7%U.S+V%R_[N?E:AX'-JF&8
MU5IUKO(Y>U,G^U36GXP,-_E/_:.M'JLW2]4W7H]3YDC"H5?KH:_"7?+X8H";
M+(7N]N770.I_QP-_(O*1N[L+]H;ST+_%IGG]XI;-K!_^3\S*SOA_PZF+0X'D
M.MYRV%VA"Z<-:7\8&=_Z]%%1>V3VUGZ/2[S/;9%+:R]/XTB4$:J)D
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MUD0      !KB]MKZ.O@/\RSBS^8W!13'>GVFS'T^X\K,E*?BX\R[QVF((Y@
M               0L^T._0\\OOR ?O0Z3'N^S3VVLOVWD*ITU_%/N=\S#1;
MC@    "\![(C][OG)]FFB?K'M :"[:/XK+_NZO?IF9:ZI=PN,#2)E@
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MPCJE2DDO>'8WF^S6NLBJ/HR2K07*L(3[K6P^:+,2ZCH4^X4CQOLPP
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M2_2*<^/GI\IOSY9T+F[K>S.7>@6_DH$74\9+G??.+!/'
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MC)25JM5V9YQZUW6I4JCQN+5NC+FCII]S8<8\\61UQ'9J-\#TD%PV"=(
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M2#PN*ZZF''C434FN:"DURI';1CM5%Q+2:BPJ420
M                    %.;N0)(^;.^_J?\ 2#'_ )$8N+L]F"__  F7?=S\
MK4-3Y_/#.*Z^,OFHYAU.G^U/6OU/^G^&_**N'J\X7^D77HU7YDB.M:B\YIZ_
M&1[Z+VX_/LW20Q][$NN@]4?C?;^1F4#>/83[17GH7^+3/([X2V;*D_\ R_\
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MB+#AQ6$-L1HL9AM*&VT)2A"$D1$1$-82E*<G*3;DWBV];?&S(/U#X
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MBI%J4[XC-/E$X1>$_$9>CKH?MEG*=S8;491^KJZ\..GQ-F9:ZGW"W^-*&4
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M\M:U=?JD1>D:<[8YRGEEEM0E'Z^6O9^!R29DVOA/F+S K^9H
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M%Z2)UEM?3ZJ2/T"G^^#;WIS!M-/SNIH>'PGQ8K\I)TO%QYB0 ><.8
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MQ3492PV8);+EACM3PQP9EVJC@_A%Q$:2,L
M               "G3W'R_[[&^O21?\ .#'_ .;_ &(Q?^@7;[+\/]AY=C]G
M/RM0T[O(Y^N[C#'#:7S8G,.J"_M2UK[HO^G^'?S?[15W] ]9G&SZHNM7\-5^
M9(C+1U/.J6A^,CWT7M!^?!O4AD[V'W@]4^GI_:^W\C,H_H,;R[!\/]Q7F/\
M)?XM,\9OKM>84MG7UW_;(K3]/^$7^+__ %%I^CR&M<:O$RUOVB?[G%+Z>O\
MS_SK_7HO^X*?=M&'^]ZF'\M2[S-K;HX^IH[6OK)=\D\&ISTX
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M>GF>[Z#4N\WX@82_W)YYYOP_8_NOJ?[:#(I]3^KPQ_+_ ,2:8>%.X
'      /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>ivvd-20250110.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2025-01-09T23:03:35.4212+00:00 -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://invivyd.com/20250110" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:ivvd="http://invivyd.com/20250110" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" namespace="http://xbrl.sec.gov/dei/2024"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" namespace="http://fasb.org/us-gaap/2024"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://invivyd.com/20250110/taxonomy/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:roleRef roleURI="http://invivyd.com/20250110/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="ivvd-20250110.xsd#DocumentDocumentAndEntityInformation" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SolicitingMaterial_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_WrittenCommunications_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Issuer Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://invivyd.com/20250110/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="49.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="50.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="51.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="52.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="53.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="54.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="55.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="56.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="57.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="58.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="59.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="60.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="61.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="62.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="63.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="64.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="65.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="66.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="67.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="68.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="69.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="70.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="71.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="72.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>6
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm45579060356400">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Jan. 10, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001832038<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jan. 10,  2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Invivyd, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40703<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">85-1403134<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1601 Trapelo Road<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 178<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Waltham<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02451<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">781<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">819-0080<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common stock, par value $0.0001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">IVVD<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>7
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MO(X%;]Z__H) =$N([F40,ZZ$M'D>$I@MM3RX4IG=3>G=*]%ZEPS;*U\+F^#
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M CQ?26D^"_;47WZT&?T+4$L#!!0    (  @Y*EJ?H!OPL0(  .(,   -
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MCVG.D4*NU"P>-8?20$3;8T.P6BP^0"X99K>]9!:G<Z17B%S7G:4]VR]/06^
MKSI,<4)I2$LS#O#-TG\R]_,,-47E2B.56QIXT^7^=N!)T:$B6!::1<G3HAVE
M?QW']I#3Z:]C(K1Z6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @
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M6@L5!K!O<B )+LF5&U)=Z7FFMW>3>TFH=>Y!L/?P&HT=S8\?M_P!4$L#!!0
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ML;S63AI_YHOA/UY_ 5!+ 0(4 Q0    (  @Y*EH'04UB@0   +$    0
M          "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ "#DJ
M6C&6G;[N    *P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N
M>&UL4$L! A0#%     @ "#DJ6IE<G",0!@  G"<  !,              ( !
MS $  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    "  (.2I:XFW]T'0$
M  # $0  &               @($-"   >&PO=V]R:W-H965T<R]S:&5E=#$N
M>&UL4$L! A0#%     @ "#DJ6I^@&_"Q @  X@P   T              ( !
MMPP  'AL+W-T>6QE<RYX;6Q02P$"% ,4    "  (.2I:EXJ[',     3 @
M"P              @ &3#P  7W)E;',O+G)E;'-02P$"% ,4    "  (.2I:
M'#AEZC\!   \ @  #P              @ %\$   >&PO=V]R:V)O;VLN>&UL
M4$L! A0#%     @ "#DJ6B0>FZ*M    ^ $  !H              ( !Z!$
M 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ "#DJ6F60
M>9(9 0  SP,  !,              ( !S1(  %M#;VYT96YT7U1Y<&5S72YX
8;6Q02P4&      D "0 ^ @  %Q0

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="ivvd-20250110.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://invivyd.com/20250110/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="ivvd-20250110.htm">ivvd-20250110.htm</File>
    <File>ivvd-20250110.xsd</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>13
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ivvd-20250110.htm": {
   "nsprefix": "ivvd",
   "nsuri": "http://invivyd.com/20250110",
   "dts": {
    "inline": {
     "local": [
      "ivvd-20250110.htm"
     ]
    },
    "schema": {
     "local": [
      "ivvd-20250110.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    }
   },
   "keyStandard": 24,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 25,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 24
   },
   "report": {
    "R1": {
     "role": "http://invivyd.com/20250110/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_c09dbd9c-d13c-4ed8-a2ee-bedecadfa843",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ivvd-20250110.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_c09dbd9c-d13c-4ed8-a2ee-bedecadfa843",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ivvd-20250110.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://invivyd.com/20250110/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://invivyd.com/20250110/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://invivyd.com/20250110/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://invivyd.com/20250110/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://invivyd.com/20250110/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://invivyd.com/20250110/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://invivyd.com/20250110/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://invivyd.com/20250110/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://invivyd.com/20250110/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://invivyd.com/20250110/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://invivyd.com/20250110/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://invivyd.com/20250110/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://invivyd.com/20250110/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://invivyd.com/20250110/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://invivyd.com/20250110/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://invivyd.com/20250110/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://invivyd.com/20250110/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://invivyd.com/20250110/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://invivyd.com/20250110/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://invivyd.com/20250110/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security 12b Title",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://invivyd.com/20250110/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://invivyd.com/20250110/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://invivyd.com/20250110/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://invivyd.com/20250110/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>14
<FILENAME>0000950170-25-003781-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-25-003781-xbrl.zip
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M0B;N*Q8@'(4V+F,"FF3[GO,1]XUH4<"TXW(CM(#ZAEH5?692[GGJ%_-T;H4
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M-()(;RH1Q5D?Y81EV"-9>B,3@TK L*V[I/7QC!@FT[#@1M@B:CE[IYQ=)C(
MY>R]XKF6LW.<#")P;4O8U'!5Y'O(?92SND.Y'HG("<.0>T_>)[=1S0V1(Y.+
MST@>J&K%M9#=&"%[C1S2'6'GMH35+4YU8TK(SN2XF8A8BVE5R5K*;KB4U35O
MB4/8OJ?I]P9@U5)V3JB(ZW&'.RK#M8':;&B9-#!M3AW7,WAH&H9C/_G<X&D&
M2I-5V9G+O(%JEYJ=1!%DM;3=&&E;62D1532<PM6]&JYN"6IL!^\>)H&KLK4,
MWG@9["\G@FL)_'@)S(1K!\SQJ.^H8#W'LFG (Y_J7*"^:SLN!.:*)?!1GO<A
MJ^7P6Y+#)J[>ZB:;A\CA4=F-E<-OQ1'W<EZ$*5-39=:'#,0,U4P2I9:K]\C,
MCY1RTZK_.H]QV+IF+9$W:HDJ/JHU2QS]6":IE:M9EON$)7;=(8F+@^@>X6!<
M3X#9LY\..U=7(E495\,."6.>YVL+45P(W:C\8>:W%<2XP63XS'&.YQE7('A#
MAR[;PRY^WUYCO&_-3#4SS0]D&J4N+04ZC'3K-\1:J MB SBW:X6Q3L>V[ D9
MWP>3!Q:C1FA:U-*-@'J^[U.F,YN#;>*O\,G.JTK''V+CI;:Q1MI0QH-4M9R&
M7]\35-G))8_[0/X+E7K&=-)3M^%UZMQKFWP\XWES4SE@VL+VJ.DSAUI6H,@8
M/.H8GAN"XWFN[SV5_D?:3:42K#/1PY<O!S5=UW2MZ!ILWS>LD%,/5$Y!QD/*
M;=>ENA$),S0=9IA//ED]ENMC^UV9X/Z6@59I(&M/J7G> 7+,<\'_)FTE^\EG
MGGV%@GSZU%KBE&1M4GS-)L6C1"CS,Y!@2,(R2!F'^15U1BA3P=V(()8YP0$"
M$L6%"N"XR-*KHJ.LV#T55<QS(B"2297QOPJ58S:Y?6/1]45%)ME6P'9WRG"Y
M<6'L!IFDI^X*4''UE2D<E2UC3EOS;C^:-*K,XM?UIIK5GA&YI?7SK5+NW,D]
M#^D>+B##]1SP"L'R_ B)R>111"TCM"C7W4BEH04;UP#=#MEJ3L>/Y_5+.:U6
M-:N5^_)6@(#2[><\P.U7+PVO<FF([A#VZD#MW)5#WCIVTL%U 6(("UP7DK1T
M4_5S*$OA-$>'6[!D=9<XJ>XQ5^1>]A4/5>=7$KM6S)W@L/%+!I<RQWJXVO D
M5#&$/ Q5PG)5."]X(G@F\NI8BUCD(S.W^<1'-KV,:&L2(;8IC  B3GW'0A%B
MH9KI0^C14 \B-PH]'YY^C>M(A S.)P"M+E#;6/GQD+ !Q6/JBOK2X:+V'1=
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M,(,"MW%UV%8=ME6';=5A6Z\V;&NW$:1BN/?=;J-3=..]_P=02P,$%     @
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M6CZ6X:%OS"UKN;UC9OG3*%I<X"0_RF 'NVH6/K:[<[HRX8(2Z*Y63HFV(C5
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MAH+/JA37264#6QDCSBTC!G,[P_TV<^05%!8=L[)]9RVH!$6FE;B_)\YFNPP
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M?WER;UZER7?_#U!+ 0(4 Q0    (  @Y*EI+ZG?%T1,  $;/   1
M      "  0    !I=G9D+3(P,C4P,3$P+FAT;5!+ 0(4 Q0    (  @Y*EI6
M:2ZF- D  *-K   1              "  0 4  !I=G9D+3(P,C4P,3$P+GAS
M9%!+ 0(4 Q0    (  @Y*EJ^K\S;NAH  !:/   /              "  6,=
G  !I=G9D+65X.3E?,2YH=&U02P4&      ,  P"[    2C@

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>ivvd-20250110_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="ivvd-20250110.xsd" xlink:type="simple"/>
    <context id="C_c09dbd9c-d13c-4ed8-a2ee-bedecadfa843">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832038</identifier>
        </entity>
        <period>
            <startDate>2025-01-10</startDate>
            <endDate>2025-01-10</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="C_c09dbd9c-d13c-4ed8-a2ee-bedecadfa843"
      id="F_9c8ac2df-68b9-403d-b9cf-c50b29b4e6fd">0001832038</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="C_c09dbd9c-d13c-4ed8-a2ee-bedecadfa843"
      id="F_2c65da4c-95a8-4673-bf11-2cdbd89cfd3e">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="C_c09dbd9c-d13c-4ed8-a2ee-bedecadfa843"
      id="F_410338d0-029b-4240-ba54-2c53e0e85591">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="C_c09dbd9c-d13c-4ed8-a2ee-bedecadfa843"
      id="F_17a0ead3-e143-4628-b8a8-a8951a0826d1">2025-01-10</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="C_c09dbd9c-d13c-4ed8-a2ee-bedecadfa843"
      id="F_052c7da8-a25d-4113-9a8b-4e7e97b7799f">Invivyd, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_c09dbd9c-d13c-4ed8-a2ee-bedecadfa843"
      id="F_64ef4eb7-76ea-4729-9de9-7cfb5dea47d9">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="C_c09dbd9c-d13c-4ed8-a2ee-bedecadfa843"
      id="F_0b31e729-c4dd-4d24-83ca-b45d888a2d2e">001-40703</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_c09dbd9c-d13c-4ed8-a2ee-bedecadfa843"
      id="F_3500c13c-406f-4c12-bd8c-9df4d2c234df">85-1403134</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_c09dbd9c-d13c-4ed8-a2ee-bedecadfa843"
      id="F_b21ff062-24a2-4d3e-811e-0d3a7d54e98a">1601 Trapelo Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_c09dbd9c-d13c-4ed8-a2ee-bedecadfa843"
      id="F_208effd1-72b0-4405-aa9b-bb5ba3eb6f24">Suite 178</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="C_c09dbd9c-d13c-4ed8-a2ee-bedecadfa843"
      id="F_73d56382-0a18-41c4-9817-e467731b3c6b">Waltham</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_c09dbd9c-d13c-4ed8-a2ee-bedecadfa843"
      id="F_541360b5-fca8-42ed-8400-574aa2dda016">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_c09dbd9c-d13c-4ed8-a2ee-bedecadfa843"
      id="F_2895713c-b89f-4df6-8d2f-473908061e81">02451</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_c09dbd9c-d13c-4ed8-a2ee-bedecadfa843"
      id="F_067a2c4e-923c-4903-a883-a8081a4ceece">781</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_c09dbd9c-d13c-4ed8-a2ee-bedecadfa843"
      id="F_9b5d0bc5-ec1c-4eb0-930d-b8febe54c53e">819-0080</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="C_c09dbd9c-d13c-4ed8-a2ee-bedecadfa843"
      id="F_18657e40-9dbe-4b63-83fc-4c731b9f0d9a">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="C_c09dbd9c-d13c-4ed8-a2ee-bedecadfa843"
      id="F_2db754d5-2701-4ca9-8316-a1fdf6ccca8e">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="C_c09dbd9c-d13c-4ed8-a2ee-bedecadfa843"
      id="F_778a6a69-402e-4c43-b35a-6782ac322659">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="C_c09dbd9c-d13c-4ed8-a2ee-bedecadfa843"
      id="F_0d75b068-9618-4645-baf9-1ad831567eb3">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="C_c09dbd9c-d13c-4ed8-a2ee-bedecadfa843"
      id="F_99e3ab40-2c34-412b-8999-0105ae535aec">Common stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_c09dbd9c-d13c-4ed8-a2ee-bedecadfa843"
      id="F_36e35d58-3906-44be-bee8-6287ce688798">IVVD</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_c09dbd9c-d13c-4ed8-a2ee-bedecadfa843"
      id="F_e59924ca-8edd-40ac-a577-12fd3c36023b">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_c09dbd9c-d13c-4ed8-a2ee-bedecadfa843"
      id="F_ce489f2b-3aff-42c4-a17f-c4de5d1315c0">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="C_c09dbd9c-d13c-4ed8-a2ee-bedecadfa843"
      id="F_53d2befa-964f-44ac-9ec8-c1bf7fc89e91">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
